SYNCAR-100 for relapsed B-ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new CAR-T cell therapy called SYNCAR-100 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. If you qualify, you would receive an infusion of specially modified immune cells designed to attack and kill leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your leukemia cells must have a protein called CD19 on their surface.
- You have B-ALL that either did not get better after two rounds of chemo, came back within a year of first remission, or returned after a stem cell transplant.
- You need to have a reasonable level of daily activity (Karnofsky score of 70 or higher) and be expected to live at least 12 more weeks.
- You cannot have had a stem cell transplant in the last 6 months, or certain severe heart or organ problems.
- You cannot have been treated with another CAR-T therapy or certain other cancer drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This trial tests an engineered immune-cell treatment (GC019F CAR-T) for adults with B-cell ALL that has come back or did not respond to prior therapy. If it works, it may help your immune system attack leukemia cells by targeting CD19.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
This trial tests a new CAR-T cell treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if these immune cells can safely and effectively fight the cancer.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.